Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe

MYC overexpression is a well-established cancer vulnerability, yet direct therapeutic targeting of Myc remains a challenge. Here, we identify DL78 as a potent antimitotic agent with selective anticancer activity through its regulation of Myc. DL78 demonstrated broad efficacy by inhibiting growth across nine cancer types and significantly reducing tumor burden in an in vivo model of platinum-resistant high-grade serous ovarian cancer, with no overt toxicity. DL78 preferentially targets chromosomally unstable, MYC-overexpressing cancer cells, a hallmark of high-grade serous ovarian cancer. Mechanistically, DL78 exploits Myc's role in mitotic entry by disrupting its interaction with α-tubulin, leading to sustained mitotic arrest, mitotic catastrophe, and apoptosis while sparing nonmalignant cells. This study establishes a novel paradigm for Myc-targeted therapy by introducing DL78, which induces cancer-selective mitotic catastrophe by disrupting Myc's interaction with α-tubulin rather than its transcriptional activity.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-10-31
DOI
https://doi.org/10.1038/s41598-025-22011-4
Primary Topic
Microtubule and mitosis dynamics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe

Sreeja C. Sekhar, Elmar Nurmemmedov, Alexander M. Sobeck, Ivan Babić et al.
Scientific Reports
Microtubule and mitosis dynamics
article

Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe

Sreeja C. Sekhar, Elmar Nurmemmedov, Alexander M. Sobeck, Ivan Babić, Yinzhi Lin, Andrew D. White, André Monteiro da Rocha, Aaron M. Robida, Ryoma Ohi, Margaret Farah, Jessica Teitel, John Takyi‐Williams, Grace McIntyre, Pil H. Lee, Jose A. Colina, Analisa DiFeo, Takashi Hotta, Bo Wen, Karan Bedi, Michele L. Dziubinski
article en

Abstract

MYC overexpression is a well-established cancer vulnerability, yet direct therapeutic targeting of Myc remains a challenge. Here, we identify DL78 as a potent antimitotic agent with selective anticancer activity through its regulation of Myc. DL78 demonstrated broad efficacy by inhibiting growth across nine cancer types and significantly reducing tumor burden in an in vivo model of platinum-resistant high-grade serous ovarian cancer, with no overt toxicity. DL78 preferentially targets chromosomally unstable, MYC-overexpressing cancer cells, a hallmark of high-grade serous ovarian cancer. Mechanistically, DL78 exploits Myc's role in mitotic entry by disrupting its interaction with α-tubulin, leading to sustained mitotic arrest, mitotic catastrophe, and apoptosis while sparing nonmalignant cells. This study establishes a novel paradigm for Myc-targeted therapy by introducing DL78, which induces cancer-selective mitotic catastrophe by disrupting Myc's interaction with α-tubulin rather than its transcriptional activity.

Scientific ReportsVol. 15(1)
University of Michigan (US), Michigan Medicine (US), Michigan Center for Translational Pathology (US), Therapeutics Systems Research Laboratories (United States) (US), BioMarin (United States) (US)
Openalex Percentile: Top 67%
Microtubule and mitosis dynamics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.